Drugs Made In America Acquisition Corp. Units (DMAAU) - Total Liabilities
Based on the latest financial reports, Drugs Made In America Acquisition Corp. Units (DMAAU) has total liabilities worth $7.36 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Drugs Made In America Acquisition Corp. generate cash to assess how effectively this company generates cash.
Drugs Made In America Acquisition Corp. Units - Total Liabilities Trend (2024–2024)
This chart illustrates how Drugs Made In America Acquisition Corp. Units's total liabilities have evolved over time, based on quarterly financial data. See DMAAU book value for net asset value and shareholders' equity analysis.
Drugs Made In America Acquisition Corp. Units Competitors by Total Liabilities
The table below lists competitors of Drugs Made In America Acquisition Corp. Units ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Changzhou Tiansheng New Materials Co Ltd
SHE:300169
|
China | CN¥804.73 Million |
|
NCT Alliance Bhd
KLSE:0056
|
Malaysia | RM998.84 Million |
|
Hansae Co
KO:105630
|
Korea | ₩825.57 Billion |
|
Timberland Bancorp Inc
NASDAQ:TSBK
|
USA | $1.74 Billion |
|
Oneconnect Financial Technology Co
NYSE:OCFT
|
USA | $1.32 Billion |
|
3I Group PLC
LSE:III
|
UK | GBX1.42 Billion |
|
Crowell Development Corp
TW:2528
|
Taiwan | NT$15.80 Billion |
|
TA-I Technology Co Ltd
TW:2478
|
Taiwan | NT$3.05 Billion |
Liability Composition Analysis (2024–2024)
This chart breaks down Drugs Made In America Acquisition Corp. Units's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see DMAAU market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Drugs Made In America Acquisition Corp. Units's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Drugs Made In America Acquisition Corp. Units (2024–2024)
The table below shows the annual total liabilities of Drugs Made In America Acquisition Corp. Units from 2024 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $795.67 | -- |
About Drugs Made In America Acquisition Corp. Units
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.